Medindia
Medindia LOGIN REGISTER
Advertisement

Daniel E. Crookshank Joins Mylan as Vice President - Investor Relations

Monday, July 21, 2008 General News
Advertisement
PITTSBURGH, July 21 Mylan Inc. (NYSE: MYL)announced today the appointment of Daniel E. Crookshank as vice president -Investor Relations and as a member of the company's senior leadership team.Reporting to Chief Financial Officer Edward J. Borkowski, Crookshank isresponsible for all investment community communication as well as for thedevelopment and direction of activities that proactively promote Mylan to theinvestment community.
Advertisement

"Dan has a well-deserved reputation as an outstanding, senior investorrelations professional," said Mylan Vice Chairman and CEO Robert J. Coury."His extensive international experience - together with his comprehensiveknowledge of finance and solid accounting background - will serve the companywell going forward. We're excited to have an individual with Dan's talentsjoining our Mylan team."
Advertisement

Crookshank served most recently as vice president - Investor Relations forRockwell Collins, a global manufacturer of communications and aviationelectronics solutions for commercial and military customers worldwide. Duringhis 18-year career with Rockwell Collins and Rockwell International, he servedin a number of increasingly responsible positions within Finance. Crookshankalso completed accounting assignments with National Steel Corporation and H.J.Heinz Corporation. He began his business career with the public accountingfirm Deloitte, Haskins & Sells, now Deloitte & Touche.

Crookshank earned a bachelor's degree in business administration fromRobert Morris University and an MBA from the Katz Graduate School of Businessat the University of Pittsburgh.

Mylan Inc., with operations in more than 90 countries, ranks among theleading diversified generic and specialty pharmaceutical companies in theworld. The company maintains one of the industry's broadest - and highestquality - product portfolios, supported by a robust product pipeline; owns acontrolling interest in the world's second largest active pharmaceuticalingredient manufacturer; and operates a specialty business focused onrespiratory and allergy therapies.

SOURCE Mylan Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close